Author: Nick Mulcahy The U.S. Food and Drug Administration has approved the first biosimilar to pegfilgrastim (Neulasta, Amgen), a granulocyte colony-stimulating factor used to reduce infection risk in patients with cancer. The new product is pegfilgrastim-jmdb ( Fulphila , Mylan GmbH), approved for use to decrease the risk for infection in patients with nonmyeloid cancer who are receiving…
Financial Stress A Key Factor In Cancer Patient Care Plan.
Patients with cancer are at a high risk for “financial toxicity,” and nurses need to be equipped to talk to them about the financial aspects of their care, according to Teresa Hagan Thomas, PhD, RN, from the University of Pittsburgh School of Nursing. It is not only the cost of treatment that contributes to financial…
GDMeds.com explore a new way to serve the people
India’s Trusted Pharmacy: Purchase Cancer Drugs Online in India No more running from one chemist store to another when in need of medicines! GDMeds.com brings to you an online medicine store, which can be accessed for all health needs. We are focused towards making healthcare accessible and affordable, especially for cancer drugs, such as chemotherapy,…
New Research: An Egg A Day Keep Heart Attack Away
Is eating eggs bad for your heart due to their high cholesterol content? You may make mistake, please think again. A large research has now shown that people who eat an egg every day could significantly reduce their risk of cardiovascular diseases. What an interesting thing. “The present study finds that there is an association between…
‘Oncology Done Right Is About Balance’: Weighing Immunotherapy Side Effects
Author: Mark G. Kris, MD Hello. This is Mark Kris from Memorial Sloan Kettering. I am speaking to you today about three papers that appeared in JAMA Oncology on January 11, 2018, dealing with the adverse effects of immune checkpoint inhibitors. There was a commentary and two papers. My issue with these presentations is the lack of discussion of benefits…
Risk of Methotrexate Dosing Errors Prompts EMA Review
Reporter: Megan Brook The European Medicines Agency (EMA) is reviewing the risk of dosing errors with medicines containing methotrexate. The review is based on “continued reports of overdose,” the agency announced today. Methotrexate is used to treat various inflammatory conditions, such as arthritis, psoriasis, and some cancers, such as acute lymphoblastic leukemia. Methotrexate can be taken…
Colorectal cancer: What are the causes, symptoms and treatment
Colorectal cancer refers to cancer that starts in the colon or rectum. It is the most common type of cancer that affects people over the age of 60 years. The three main symptoms of colorectal cancer are: Persistent blood in the stools – occurs for no obvious reasons and associated with a change in the…
Rucaparib for Ovarian Cancer OK’d for Approval in Europe
Reporter: Zosia Chustecka A new option for the treatment of ovarian cancer could soon be available in Europe: the PARP (poly [adenosine diphosphate-ribose] polymerase) inhibitor rucaparib (Rubraca, Clovis). At its latest meeting the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA) recommended a conditional marketing authorization for rucaparib…
Clinicians as Communication Coaches – Preparing Patients for Difficult Conversations
Author: Betty R. Ferrell, PhD, RN Tired of Treatment Paulo is a 49-year-old man with a recurrent brain tumor; he is now hospitalized after experiencing seizures. The tumor was diagnosed when Paulo was 44 years of age, and he has had extensive surgery, chemotherapy, and radiation therapy. Three months ago, the brain tumor team advised Paulo…
How smoking ruins your lungs
Smoking is one of the main causes of preventable deaths throughout the world. When smoke enters the human body it affects nearly each and every organ leading to many life-threatening diseases. The poisons from the cigarette, which are basically tar and other chemicals when entering the bloodstream, are responsible for narrowing the arteries as well as…
